Eberling v. Secretary of Health and Human Services
Opinion
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS No. 22-0778V
ANDREW EBERLING,
Chief Special Master Corcoran Petitioner, v.
Filed: September 10, 2024 SECRETARY OF HEALTH AND HUMAN SERVICES,
Respondent.
Adam Marc Raditz, Ginsberg & O’Connor, P.C., Cherry Hill, NJ, for Petitioner. Julianna Rose Kober, U.S. Department of Justice, Washington, DC, for Respondent.
RULING ON ENTITLEMENT1
On July 18, 2022, Andrew Eberling filed a petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.2 (the “Vaccine Act”). Petitioner alleges that he suffered a syncopal episode upon receiving a human papillomavirus (“HPV”) vaccine on August 2, 2019, which resulted in injuries, including a “closed nasal fracture and deviated septum with 85% obstruction” and lacerations to his face.” Petition at 1-2. The case was assigned to the Special Processing Unit of the Office of Special Masters.
On September 10, 2024, Respondent filed his Rule 4(c) report in which he concedes that Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 1. Specifically, Respondent states that, “petitioner has satisfied the criteria set forth in the recently revised Vaccine Injury Table and its Qualifications and Aids to Interpretation, which afford petitioner a presumption of causation if the onset of vasovagal syncope occurs within one hour after an HPV vaccination and there is no apparent alternative cause.” Id. at 3. Respondent further agrees that “petitioner experienced more than six months of residual effects. Specifically, the six-month severity requirement is met via the deviated septum from August 2, 2019, to about January 2023.” Id.
In view of Respondent’s position and the evidence of record, I find that Petitioner is entitled to compensation.
IT IS SO ORDERED. s/Brian H. Corcoran Brian H. Corcoran Chief Special Master
Case-law data current through September 30, 2026. Source: CourtListener bulk data.